CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation

Cancer Research

Volumn 73, Issue 22, 2013, Pages 6722-6733

  Yang, Shuping ^a,b   Zhang, Lin ^a,b   Liu, Miao ^b   Chong, Rong ^a   Ding, Shi Jian ^a,b   Chen, Yuanhong ^a   Dong, Jixin ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE 1; ONCOPROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL TRANSFORMATION; CENTROSOME; CHROMOSOME SEGREGATION; COMPLEX FORMATION; CONTROLLED STUDY; EPITHELIUM CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MITOSIS; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; CDC2 PROTEIN KINASE; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HUMANS; MCF-7 CELLS; MITOSIS; NOCODAZOLE; NUCLEAR PROTEINS; PACLITAXEL; PHOSPHORYLATION; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84888309765     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2049     Document Type: Article

References (53)

1. Pan D. Hippo signaling in organ size control. Genes Dev 2007;21:886-97.
2. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010;19:491-505.
3. Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer 2013;13:246-57.
4. Zhao B, Tumaneng K, Guan KL. The hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011;13:877-83.
5. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22:1962-71.
6. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012;26:1300-5.
7. Miller E, Yang J, DeRan M, Wu C, Su AI, Bonamy GM, et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem Biol 2012;19:955-62.
8. Mo JS, Yu FX, Gong R, Brown JH, Guan KL. Regulation of the hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev 2012;26:2138-43.
9. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012;150:780-91.
10. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-61.
11. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010;24:72-85.
12. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008;283:5496-509.
13. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell 2007;130:1120-33.
14. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011;144:782-95.
15. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006;103:12405-10.
16. Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of yes-associated protein (yap) overabundance. Proc Natl Acad Sci U S A 2011;108:E1312-20.
17. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009;16:425-38.
18. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 2010;107:1431-6.
19. Nishio M, Hamada K, Kawahara K, Sasaki M, Noguchi F, Chiba S, et al. Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. J Clin Invest 2012;122:4505-18.
20. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010;107:1437-42.
21. Hergovich A, Hemmings BA. Hippo signalling in the G2/M cell cycle phase: lessons learned from the yeast MEN and SIN pathways. Semin Cell Dev Biol 2012;23:794-802.
22. Zhang L, Iyer J, Chowdhury A, Ji M, Xiao L, Yang S, et al. KIBRA regulates aurora kinase activity and is required for precise chromosome alignment during mitosis. J Biol Chem 2012;287:34069-77.
23. Xiao L, Chen Y, Ji M, Volle DJ, Lewis RE, Tsai MY, et al. KIBRA protein phosphorylation is regulated by mitotic kinase aurora and protein phosphatase 1. J Biol Chem 2011;286:36304-15.
24. Ji M, Yang S, Chen Y, Xiao L, Zhang L, Dong J. Phospho-regulation of KIBRA by CDK1 and CDC14 phosphatase controls cell-cycle progression. Biochem J 2012;447:93-102.
25. Xiao L, Chen Y, Ji M, Dong J. KIBRA regulates hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem 2011;286:7788-96.
26. Ding SJ, Li Y, Shao XX, Zhou H, Zeng R, Tang ZY, et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004;4:982-94.
27. Liu M, Hou J, Huang L, Huang X, Heibeck TH, Zhou R, et al. Site-specific proteomics approach for study protein S-nitrosylation. Anal Chem 2010;82:7160-8.
28. Geer LY, Markey SP, Kowalak JA, Wagner L, Xu M, Maynard DM, et al. Open mass spectrometry search algorithm. J Proteome Res 2004;3:958-64.
29. Hirota T, Morisaki T, Nishiyama Y, Marumoto T, Tada K, Hara T, et al. Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. J Cell Biol 2000;149:1073-86.
30. Morisaki T, Hirota T, Iida S, Marumoto T, Hara K, Nishiyama Y, et al. WARTS tumor suppressor is phosphorylated by Cdc2/cyclin B at spindle poles during mitosis. FEBS Lett 2002;529:319-24.
31. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006;20:2687-700.
32. Lee KK, Yonehara S. Identification of mechanism that couples multisite phosphorylation of yes-associated protein (YAP) with transcriptional coactivation and regulation of apoptosis. J Biol Chem 2012;287:9568-78.
33. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by cabl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 2008;29:350-61.
34. Tomlinson V, Gudmundsdottir K, Luong P, Leung KY, Knebel A, Basu S. JNK phosphorylates yes-associated protein (YAP) to regulate apoptosis. Cell Death Dis 2010;1:e29.
35. Matson DR, Stukenberg PT. Spindle poisons and cell fate: a tale of two pathways. Mol Interv 2011;11:141-50.
36. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20:147-55.
37. Du L, Lyle CS, Chambers TC. Characterization of vinblastine-induced bcl-xL and bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 2005;24:107-17.
38. Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1- mediated bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010;30:640-56.
39. Nigg EA. Cellular substrates of p34(cdc2) and its companion cyclin-dependent kinases. Trends Cell Biol 1993;3:296-301.
40. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 2008;105:10762-7.
41. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 2010;3:ra3.
42. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the drosophila hippo pathway. Cancer Res 2008;68:2789-94.
43. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 2012;109:E2441-50.
44. Ogden A, Rida PC, Aneja R. Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration. Cancer Metastasis Rev 2013;32:269-87.
45. Mardin BR, Lange C, Baxter JE, Hardy T, Scholz SR, Fry AM, et al. Components of the hippo pathway cooperate with Nek2 kinase to regulate centrosome disjunction. Nat Cell Biol 2010;12:1166-76.
46. Yabuta N, Okada N, Ito A, Hosomi T, Nishihara S, Sasayama Y, et al. Lats2 is an essential mitotic regulator required for the coordination of cell division. J Biol Chem 2007;282:19259-71.
47. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85.
48. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 2009;10:478-87.
49. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
50. Chan JY. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 2011;7:1122-44.
51. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37.
52. Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol 2008;18:311-21.
53. Toji S, Yabuta N, Hosomi T, Nishihara S, Kobayashi T, Suzuki S, et al. The centrosomal protein Lats2 is a phosphorylation target of aurora-A kinase. Genes Cells 2004;9:383-97.